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Background: Dupuytren’s contractures are fibrous cords under the skin of the palm of the hand. The contractures
are painless but cause one or more fingers to curl into the palm, resulting in loss of function. Standard treatment
within the NHS is surgery to remove (fasciectomy) or divide (fasciotomy) the contractures, and the treatment
offered is frequently determined by surgeon preference. This study aims to determine the feasibility of conducting
a large, multicentre randomised controlled trial to assess the clinical and cost-effectiveness of needle fasciotomy
versus limited fasciectomy for the treatment of Dupuytren’s contracture.
Methods/design: HAND-1 is a parallel, two-arm, multicentre, randomised feasibility trial. Eligible patients aged
18 years or over who have one or more fingers with a Dupuytren’s contracture of more than 30° in the
metacarpophalangeal (MCP) and/or proximal interphalangeal (PIP) joints, well-defined cord(s) causing contracture,
and have not undergone previous surgery for Dupuytren’s on the same hand will be randomised (1:1) to treatment
with either needle fasciotomy or limited fasciectomy. Participants will be followed-up for up to 6 months post
surgery. Feasibility outcomes include number of patients screened, consented and randomised, adherence with
treatment, completion of follow-up and identification of an appropriate patient-reported outcome measure (PROM)
to use as primary outcome for a main trial. Embedded qualitative research, incorporating a QuinteT Recruitment
Intervention, will focus on understanding and optimising the recruitment process, and exploring patients’
experiences of trial participation and the interventions.
Discussion: This study will assess whether a large multicentre trial comparing the clinical and cost-effectiveness of
needle fasciotomy and limited fasciectomy for the treatment of Dupuytren’s contractures is feasible, and if so will
provide data to inform its design and successful conduct.
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Dupuytren’s contractures are fibrous cords under the skin
of the palm of the hand which typically occur in men and
women over 50 years of age. They have a strong genetic
tendency [1] and an increased incidence associated with
diabetes and epilepsy [2]. The contractures are painless
but cause one or more fingers to gradually curl into the
palm, resulting in loss of hand function. This can lead to
loss of dexterity for day-to-day tasks such as washing,
grooming and shaking hands. It becomes increasingly dif-
ficult to put on a glove, hold large objects or put the hand
in a pocket. Other difficulties experienced are diverse and
patient dependent, and can include computer use, baking,
piano playing, carpentry, gardening, and sports such as
cycling, golf and tennis [3–5].
The standard treatment is surgery to remove (fasciect-
omy) or divide (fasciotomy) the Dupuytren’s contractures,
allowing the finger to straighten better. However, this does
not cure the condition, the finger may not come fully
straight and recurrent contractures may require further
surgery. In 2010–2011 it was estimated that the total cost
of Dupuytren’s contractures procedures in England was
more than £41 million with increasing rates of primary
and revision procedures [6]. Increased longevity in an
ageing population may cause a 77% increase in demand
for treatment by 2030 [7].
There are no agreed criteria for choice of surgical treat-
ment of Dupuytren’s contractures, but guidelines have
been produced for one treatment, ‘needle fasciotomy’ (NF)
[8]. The most common operation currently in the UK is
‘limited fasciectomy’ (LF), in which the fibrous cords
preventing the finger from straightening are cut out of the
hand through a long skin incision. This procedure is done
under general or regional anaesthesia in an operating
theatre, typically as a day-case admission and has a 4–6-week
recovery period. Around 13,000 LFs were carried out in
England in 2014–2015 [9]. A common alternative treatment
is NF. In this procedure the fibrous cords preventing the
finger(s) from straightening are divided with the sharp tip of
a hypodermic needle which is passed through the skin
without the need for a skin incision. It can be done in an
outpatient clinic room and has a 1–2-week recovery period.
Around 1300 NFs were recorded in UK Hospital Episode
Statistics during 2014–2015, although this may be an
underestimate if procedures performed in outpatient
rooms are under-recorded [9].In comparison to LF, NF is likely to be less expensive
for health services, less disruptive for patients, and
potentially carries a lower risk of complications that
restrict hand function (temporarily or permanently)
after the surgery [10]. Contractures can reform in the
fingers that have been operated on after either treat-
ment, causing the finger to bend up into the palm
again, but recurrence occurs earlier and more
frequently with NF, and may result in a need for fur-
ther treatment [11]. There are three subtypes of
Dupuytren’s contractures, those which affect the meta-
carpophalangeal (MCP) joint alone, the proximal
interphalangeal (PIP) joint alone, or both the MCP
and PIP joints. Both procedures can successfully
straighten fingers with a Dupuytren’s contracture in-
volving only the MCP joint. However, fingers with
contractures involving the PIP joint cannot always be
fully straightened with surgery, though LF is more
successful and allows for the option of a PIP joint
capsule release, if necessary.
There is no high-quality evidence comparing surgi-
cal treatments for Dupuytren’s contracture. One sys-
tematic review in 2010 found only five randomised or
pseudo-randomised trials evaluating the surgical
treatment of Dupuytren’s contracture [12], and a sub-
sequent Cochrane systematic review found insufficient
evidence to show the relative superiority of different
surgical procedures (including NF versus fasciectomy)
[13]. Although one small randomised controlled trial
(RCT) comparing NF with LF showed a higher recur-
rence rate after NF at 5 years [11], it had methodo-
logical weaknesses, resulting in high risks of attrition,
performance and detection bias [13], and did not rigor-
ously compare hand function. Furthermore, recurrence
should not be considered as indicating failure of the
procedure, as it may not be sufficiently severe to warrant
‘revision surgery’ and may be managed by a further NF,
with minimal inconvenience to the patient [14]. Also NF
is cheaper and has a shorter recovery period than LF [10],
and may produce as good hand function at 1- and 5-year
follow-up [15].
Existing studies comparing NF with LF have a
number of limitations; most importantly, high risk of
performance and detection biases and the use of
angular measurements of finger straightness and
recurrence as primary outcomes rather than a patient-
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of hand function. Also, none assessed the cost of treat-
ments to either providers or patients, and none rigor-
ously compared the outcomes of NF with LF in each
of the three subtypes of Dupuytren’s contracture. The
subtype, which only affects the MCP joint (40% of all
contractures), is most likely to correct successfully
with NF with the least risk of damage to the digital
nerves and tendons [10, 11]. Surgeons are most com-
fortable treating this subtype by NF [16] and it may be
a specific subgroup for which NF provides equivalent
or better outcomes than LF.
Although function is the main problem for patients
with Dupuytren’s contracture, there is no consensus
about the most appropriate PROMs to assess the
outcome of treatment. Most PROMs used in hand
surgery are not specific to this condition. Thirteen
small studies (four retrospective and six prospective
cohort and three RCTs) have used PROMs as an out-
come measure for Dupuytren’s contracture [17]. They
used the DASH (11 studies), the QuickDASH, Part 2
of the Patient Evaluation Measure (PEM) and the
Unité Rhumatologique des Affections de la Main
(URAM) (one study each). Although improvements in
hand function have been recorded with all after
surgery, the minimal clinically important difference
(MCID) for patients with Dupuytren’s contracture has
only been calculated for the URAM, which may not
adequately assess loss of hand function with Dupuytren’s
contracture [5].
The lack of well-designed and well-conducted trials
means that the choice of treatment for Dupuytren’s
contractures of the fingers mainly depends on surgeon
and patient preference. A survey of 116 hand surgeons
showed marked variations in treatments advised for
Dupuytren’s contractures [16]. The same surgeons re-
ported that the most important research question about
surgical treatment was a comparison of NF with LF. This
is also an important question for patients. A recent sur-
vey [5] of 110 patients awaiting surgery found that the
most important factors in deciding which treatment to
undergo were recurrence (38%), surgeon guidance (37%)
and speed of recovery following surgery (25%). There
is an urgent need for robust evidence to guide
decision-making.
In summary, a high-quality definitive trial comparing
the outcomes and costs of NF with LF in patients with
Dupuytren’s contracture of the MCP joint and/or PIP
joint is needed. This study aims to assess the feasibility
of a large multicentre trial, and to inform its design and
conduct, including providing information about num-
bers of eligible patients, recruitment and randomisation,
completion of follow-up, selection of appropriate out-
come measures, and sample size.Objectives
The objectives of the study are to:
1. Define the eligibility criteria for a future, definitive
randomised trial comparing NF with LF
2. Estimate the proportion of referred NHS patients
with Dupuytren’s contractures who meet these
eligibility criteria
3. Determine the willingness of surgeons to recruit
patients with different patterns of Dupuytren’s
contractures of the fingers
4. Estimate the proportion of eligible patients who
consent to randomisation
5. Assess and optimise the recruitment process and
patient pathway using a QuinteT Recruitment
Intervention (QRI) [18]
6. Estimate follow-up and outcome completion rates
7. Evaluate outcomes for use as primary and secondary
outcomes in the definitive study
8. Assess and compare validity and reproducibility of
two methods of measurement of finger straightness
which can be performed by a research assistant
9. Determine standard practice and equipment for
clinic room provision of treatment
10.Assess the relationship between angular
measurements of the finger deformity and patients’
reported outcomes
11.Evaluate the utility and acceptability of health
resource use questionnaires to assess the impact of
care on health service use and productivity
12.Assess patient and staff views on trial conduct, trial
participation, and acceptability of interventions using
qualitative research methods
13.Calculate the sample size required for a definitive
study
Methods/design
The HAND-1 study is a parallel, two-arm, randomised
feasibility trial with participants individually allocated on a
1:1 ratio to treatment with either LF in an operating the-
atre, or NF in a clinic room. Participants will be followed
up for up to 6 months post treatment. Embedded qualita-
tive research incorporating a QRI [18] will focus on under-
standing and optimising the process of recruiting to the
trial, and explore patients’ experiences of trial participation
and the interventions. Audio-recordings of recruitment
consultations will be a key method used to understand the
recruitment process, along with regular monitoring of
screening logs and interviews with trial staff and patients.
Flow of participants through the study is summarised
in Fig. 1.
The HAND-1 study will inform the design and con-
duct of a large multicentre trial to compare the clinical
and cost-effectiveness of the two treatments.
Fig. 1 Trial flow diagram
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Recruitment will take place in three secondary care sites
in England: Derby Teaching Hospitals NHS Foundation
Trust, Wrightington, Wigan and Leigh NHS Foundation
Trust and Nottingham University Hospitals NHS Trust/
Nottingham Treatment Centre.
Patients are eligible for the study if they are aged over
18 years, have one or more fingers with a Dupuytren’s
contracture of more than 30° in the MCP and/or PIP
joints, have a well-defined cord causing contracture,
have had no previous surgery for Dupuytren’s contrac-
ture on the same hand, are willing to undergo either
study procedure, and are able to complete the follow-up
assessments. Exclusion criteria are Dupuytren’s contrac-
ture of the distal interphalangeal joints (DIP) only,
having a planned dermofasciectomy or very limited
fasciectomy (excision of up to 1 cm of cord segment),
previous recruitment into the study, or a life expectancy
of less than 3 years.
Interventions
The two interventions are NF and LF. Following ran-
domisation, participants will be placed on the NHSwaiting list for their allocated treatment, which will be
carried out by a competent surgeon (consultant or experi-
enced trainee, or an inexperienced trainee under direct
supervision of their trainer). The level of experience of the
surgeon and key elements of the procedure, including
start and end times and equipment used, will be recorded.
Needle fasciotomy
The procedure will be performed in a clinic room (not
an operating theatre) equipped with a good ‘clinic room’
spotlight, wound swabs, a couch and possibly an arm
board. The hand will be rested appropriately to allow full
extension of the affected finger (to put the cord under
tension). The cord must only be cut and no segment
must be excised. A small amount of local anaesthetic is
injected at the site of each point of division of the cord.
The number of points along the cord at which division
is attempted and choice of needle size is at the discretion
of the surgeon. The use of a knife is permitted, but no
tourniquet or other surgical instruments will be allowed.
Either a multiple stabbing technique or a side-to-side
cutting action can be used to divide the cord(s) in as
many places as indicated.
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The planned operation must be a LF (excision of more
than 1 cm of cord), and not a very limited fasciectomy
or a dermofasciectomy. This will be performed under
either general or regional anaesthetic with the use of a
tourniquet. The contracture will be exposed through a
standard surgical incision. For contractures involving the
MCP joint the Dupuytren’s cord must be excised prox-
imally to at least the proximal margin of the transverse
fibres of the palmar aponeurosis. Digital cords should be
excised completely from their origin. In all cases the dis-
tal margin of the cord excision should be the insertion
of the cord onto the flexor sheath (or other structure).
Deviations from ‘limited fasciectomy’ (for example, a
decision made during surgery based on unexpected
operative findings to use a skin graft) will be recorded,
as will the use of additional procedures such as release
of a joint contracture.
If a patient presents with two or more fingers on the
same hand that require treatment, then both/all fingers
will be treated in the same manner (i.e. both/all with LF
or both/all with NF). For any study outcomes that
require reference to a single finger, the finger which the
patient reports pre-operatively as causing the most
trouble will be used.
Outcomes
Patient-reported outcome measures (PROMs)
A range of outcome measures were identified as being
potentially useful for a large-scale trial, one of the main
goals for this study being to determine their appropriate-
ness and usability. These included validated questionnaires
on physical function and symptoms, changes in wellbeing
and health outcomes. Participants in both study arms will
be asked to complete the same series of PROMs at baseline
and at 2-week, 6-week and 6-month follow-up as follows:
1. Unité Rhumatologique des Affections de la Main
(URAM) [19]
2. Disabilities of the Arm, Shoulder and Hand
Questionnaire (DASH) [20, 21]
3. Part 2 of the Patient Evaluation Measure (PEM) [22]
4. Measure Yourself Medical Outcome Profile
(MYMOP) [23]
5. EQ-5D-5 L descriptive system [24]
In addition, PEM will be completed on the day of
surgery prior to treatment. This provides a check if
symptoms have progressed differentially during this
period, as waiting times from randomisation to surgery
may differ for the two interventions.
Other clinical outcome measures
The following data will be collected at follow-up:1. Global Improvement Item [23] – self-completed by
participants (to act as the anchor for the assessment
of the performance of the PROMs)
2. Complications following surgery
3. NHS resource use – patient-reported and obtained
from medical records
4. Return to work/usual activities
The following objective outcomes will be measured at
baseline and at 6-week and 6-month follow-up clinic
visits:
1. Grip strength
2. Angular measurement of finger straightness, with
photographs taken for blinded assessment
Standardised photographs will be taken using the
Nottingham Dupuytren’s Assessor which has been devel-
oped for the purposes of the study.
Sample size
As this is a feasibility study, a formal sample size calcula-
tion is not appropriate. It is anticipated that 50–85
participants will be recruited across the three sites. One
of the primary aims of this feasibility study is to estimate
response to invitation, eligibility, consent, randomisation
and follow-up. Based on an expected total number to be
invited of 400, estimated margins of error for these
proportions will range between 5 and 13%.
Recruitment and follow-up
Recruitment will take place from November 2015 to
September 2016. Participants will be recruited from sec-
ondary care clinics at three sites in England. Patients
who are referred by their general practitioner (GP) to
the hand surgery outpatient clinic will be sent a short
Patient Information Leaflet before their appointment
which will explain Dupuytren’s contracture of the fingers
and that they may be invited to participate in the study
during their clinic visit. The leaflet will also explain that
they may be asked for permission to audio-record con-
sultations with the surgeon and research nurse/assistant
during the clinic visit. These audio-recordings form part
of the QRI and will help to understand and optimise the
recruitment process. Trial posters will also be displayed
in waiting areas in recruiting clinics to raise awareness
of the study.
Following randomisation, participants are placed on the
NHS waiting list for their allocated treatment, and each
participant is followed up for 6 months following their
surgery. At the end of the follow-up period information
from the medical records will be extracted to record any
outpatient appointments, outpatient procedures, emer-
gency department visits or inpatient admissions related to
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Participants may be invited to take part in qualitative
interviews up to 6 months after treatment.
Upon completion of all trial visits and questionnaires,
participants will receive an end-of-study letter accom-
panied by an Information Sheet thanking them and
informing them that their participation in the study is
complete. Details of the data collection schedule are
summarised (see Fig. 2).
Consent
Participant Information Sheets (PIS) will be provided to
patients and they will have the opportunity to discuss the
study before agreeing to take part. Written informed
consent will be obtained from all participants. Written
consent for audio-recording consultations will be obtainedFig. 2 Schedule of data collection for the HAND-1 feasibility study (Standa
(SPIRIT) figure)separately from consent for the main study. The investiga-
tor, or their nominee, and the participant or other legally
authorised representative will both sign and date the
Informed Consent Form.
No trial-specific procedures will be conducted before
informed consent has been obtained, and participants
will be reminded that they may withdraw from the trial
at any time without it affecting the quality of their care
in the future.
Randomisation
Participants will be randomly allocated to treatment, in
a 1:1 ratio, to treatment with either LF in an operating
theatre, or NF in a clinic room, via a secure web-based
system which is maintained by the Nottingham Clinical
Trials Unit (NCTU) in accordance with their standardrd Protocol Items: Recommendations for Interventional Trials
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stratified by recruiting site and the joints affected, and
will use computer-generated, permuted, balanced blocks
of randomly varying size. Investigators and research
nurses will access the randomisation website by means
of a remote, Internet-based randomisation system devel-
oped and maintained by the NCTU. Participants will be
informed orally of their treatment allocation at the point
of randomisation. Participants and their GPs will also be
notified of the allocation by letter.
Blinding
Blinding of the surgeon and/or participant is not pos-
sible as it will be clear which treatment the participant
receives. Photographic evidence of contracture at the
6-month follow-up will be reviewed by an assessor blind
to the treatment allocation, as the participant will be
asked to wear a latex glove, with the tip for the study
finger cut off, which will hide any surgical scars. Trial
statisticians will be blinded to treatment allocation until
database lock.
Adverse events
Both interventions in the study are widely used within
current NHS practice. As such, collection of adverse
events (AEs), beyond those listed as trial outcomes, is
limited to recording serious adverse events (SAEs). SAEs
that will be reported are death, loss of a finger and any
unexpected and serious event that is potentially related
to the intervention. If site staff become aware of an SAE,
they will complete an SAE Report Form which will be
emailed or faxed to the NCTU within 24 h, and then
forwarded to the medical monitor for assessment.
Data collection, management and analysis
Data collection, clinical assessments and taking of digital
images will be carried out by trained site staff. Partici-
pant questionnaires at baseline, day of surgery, 6 weeks
and 6 months will be self-completed by participants
during the clinic visit. Follow-up at 2 weeks will be via
postal questionnaire.
If postal follow-up questionnaires are not returned, a
telephone call will be made or a reminder letter sent
from the NCTU to follow up with the participant.
Participants who do not receive their allocated proced-
ure will continue to be followed up unless they opt to
withdraw from the trial completely. Participants who fail
to attend the clinic visit at 6 weeks will still be invited to
attend at 6 months unless they opt to withdraw from
trial follow-up.
Data collection and retention rates will be monitored
by the Trial Management Group (TMG) throughout
the trial.Data management and monitoring
The NCTU will undertake data management and ensure
that the trial is conducted according to Good Clinical
Practice (GCP) guidelines and SOPs. Data will be
collected and retained in accordance with the Data
Protection Act 1998. Clinic data will be either entered
directly into a web-based trial database at recruiting
sites, or recorded on a paper worksheet and transcribed
into the database, by site users with unique login details.
Participant questionnaires completed at clinic visits will
be transcribed by site staff into the trial database. Postal
paper questionnaires will be returned in a reply paid
envelope to the NCTU for data entry into the trial
database.
Data quality will be ensured by database validation
checks which include missing data, out-of-range values,
illogical entries and invalid responses. Data entered by
sites into the trial database will be subject to monitoring
and review by NCTU staff, and data queries will be
raised as necessary. Detailed data management processes
and procedures are documented in the HAND-1 Data
Management Plan.
Monitoring of study data will be by a combination of
central and on-site monitoring, in accordance with the
risk-based Monitoring Plan. The chief investigator (CI)
has overall responsibility for the study and is custodian
of the data.
Statistical analyses
The analysis and reporting of the trial will be in accord-
ance with extensions of the Consolidated Standards of
Reporting Trials (CONSORT) Guidelines for Pilot and
Feasibility Trials [25] and Non-Pharmacologic Treat-
ment Interventions [26].
Continuous variables will be summarised in terms of
the mean, standard deviation, median, lower and upper
quartiles, minimum, maximum and number of observa-
tions. Categorical variables will be summarised in terms
of frequency counts and percentages. A CONSORT flow
diagram showing the numbers of people approached,
eligible, recruited and randomised (with reasons for
exclusions) will be produced. Recruitment rates at the
start and end (after modification of the recruitment
method based on the qualitative studies) of the recruit-
ment phase of the study will be compared. Numbers and
characteristics of participants recruited will be sum-
marised using appropriate descriptive statistics and com-
pared with patients who were eligible but not randomised.
Completeness of data collection will be compared
between trial arms. A Statistical Analysis Plan (SAP) will
be agreed before data are unblinded.
We will ‘micro-cost’ [27] NF and LF by combining
resource use with unit costs provided by the hospital
finance departments. Standard unit costs will be used to
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procedure [28, 29]. Descriptive summaries of NHS cost
data and return to work/usual activities at each follow-up
time point will be presented.
Minimum clinically important effects for each PROM
will be estimated using three anchor-based responsiveness
statistics: (1) standardised response mean (SRM), (2) effect
size (ES) and (3) Guyatt’s Responsiveness Index (GRI).
This analysis will guide the choice of PROM for use in a
definitive trial of treatment of Dupuytren’s disease, along
with participant ranking of the different PROMs.
Improvements in the ability to extend the finger(s)
after surgery will be compared with these responsiveness
indices to investigate its use as a surrogate measure of
hand function and calculate its minimum clinically
important difference (MCID).
Qualitative methods
Qualitative research will be integrated into the study to
provide fundamental insights into the feasibility and de-
sign of a main trial. A QuinteT Recruitment Intervention
(QRI) will be implemented to optimise trial recruitment
[18], and further qualitative methods will be employed
to explore patients’ experience of trial participation and
the interventions.
QuinteT Recruitment Intervention
The QRI aims to understand the recruitment process and
how it operates in each of the clinical centres. Sources of
recruitment difficulties can then be identified and sugges-
tions made to change aspects of the design, conduct,
organisation or training that could then lead on to im-
provements in recruitment. The QRI will be flexible in its
intensity and comprehensiveness to operate in the most
effective way for the feasibility study. It will be undertaken
in three distinct, but overlapping, phases.
Phase 1 seeks to understand the recruitment process
as it occurs. A multifaceted, flexible approach will be
adopted using one or more of the following methods
until the point of data saturation – when new data does
not materially add to the findings:
1. Monitoring the patient pathway through eligibility
and recruitment
All study centres will be asked to maintain detailed
trial screening logs. This will record the details of
patients who are, or are not, screened for trial entry,
reasons for ineligibility and details of eligible patients
who do not consent to trial participation and
randomisation. These logs will be monitored
regularly to identify patterns relating to recruitment
rates, reasons for ineligibility, and points at which
patients do not continue with trial recruitment.
2. Audio-recording of recruitment appointmentsAll consultations in which the trial is discussed and
the patient is offered participation in the trial will be
audio-recorded following patient consent. The
audio-recordings will be used to explore information
provision, recruitment techniques, patient treatment
preferences, and randomisation decisions to identify
recruitment difficulties and improve information
provision. The qualitative researcher will listen to
appointments and document relevant details which
will form the basis for individual confidential feedback
and trial-specific training.
3. Semi-structured interviews
Semi-structured interviews will be conducted with
trial management and recruiting staff to assess their
views on the trial and its conduct, including
knowledge of the evidence and personal views about
the interventions. Recruiters will also be asked how
they explain the study to patients and perceived
barriers to recruitment. Interviews may also be
undertaken with a purposeful sample of up to 30
eligible patients soon after the offer of trial
participation to explore their views on the trial and
recruitment process, presentation of study
information, study documentation and reasons for
accepting or declining randomisation. A maximum
variation sampling strategy [30] will be employed to
ensure that a broad range of patients are captured.
Interview topic guides will be used to ensure similar
areas are covered in each interview within each group,
based on those used in previous studies [31, 32], but
will be sufficiently flexible to encourage the informants
to express their own views about the study and any
recruitment challenges expected or experienced.
4. Observations of investigator meetings
Meetings between the CI, the Trial Management
Group (TMG) and clinical investigators to discuss
progress with the trial may be observed and audio-
recorded to gather information about specific issues
that may have a bearing on recruitment.
5. Study documentation
Participant Information Sheets (PIS) and Consent
Forms may be scrutinised to identify aspects that are
unclear or potentially open to misinterpretation. They
will be compared with the findings from the
interviews and recorded appointments to identify any
discrepancies or improvements that could be made.
In phase 2, the qualitative team will present summaries
of anonymised findings from phase 1 to the CI and study
management team, highlighting any factors that appear to
be affecting recruitment with supporting evidence. It is
likely that some aspects will be generic, such as how to
explain randomisation and deal with patient preferences,
as well as issues specific to the study. A plan of action will
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clude training sessions for recruiters, in which results are
fed back and areas of difficulties addressed, recruitment
tips documents, re-drafting study information to provide
balanced information and changing aspects of organisa-
tion in clinical centres.
Numbers of eligible patients, and the percentages of
these that are approached about the RCT, consent to be
randomised and immediately accept or reject the alloca-
tion will be assessed in phase 3 before the plan of action
is implemented, and regularly afterwards to check
whether rates are improving. Follow-up interviews may
also be conducted with the trial recruiters to ascertain
their views on the acceptability of the QRI and any
changes that may have occurred as a result.Patients’ experience of trial participation and interventions
Semi-structured interviews will be undertaken with up to
30 trial participants within 6 months of receiving treat-
ment to understand their experience with, and acceptabil-
ity of, the treatment, outcome measures and wider trial
processes. The final sample size will be driven by data sat-
uration. Where possible, patients who were interviewed
earlier on in the trial will be contacted again for this
interview, or new patients will be purposefully sampled to
ensure a broad range of participants. Topic guides will be
used to ensure that similar topics are covered in each
interview but applied in a flexible manner, enabling issues
of importance to the patients to emerge. The guide will
focus on their experiences of living with Dupuytren’s con-
tracture pre and post intervention, previous experiences
of treatment, recovery post intervention, views on the
treatment received, the suitability and ease of understand-
ing and completing the hand function outcome measures,
and their reflections on participating in the trial.Qualitative data analysis
Interviews and recruitment consultations will be audio-
recorded, fully transcribed and, along with recruitmentTable 1 Summary of amendments to the HAND-1 feasibility study p
Protocol Date Summary of changes prio
v 1.1 27 Aug 2015 • Minor administrative and
• Clarification that if a part
will be treated in the sam
fasciotomy). For any stud
patient reports pre-opera
Protocol Date Summary of changes afte
v 2.0 21 Jun 2016 • Modification to 6-month
within the study follow-u
will be followed up via p
• Clarification that the qua
Bristol, and that participa
qualitative researcher at
• Clarification of serious adscreening logs and observations, subject to simple counts,
content, thematic and targeted conversation analyses.
Preliminary analysis will be used to inform training and
further data collection. Members of the qualitative team
will independently analyse a proportion of transcripts to
assess the dependability of coding, and will meet regularly
to review coding and descriptive findings, agree further
sampling and training strategies, and discuss theoretical
development – all in close collaboration with the CI.
Results from the qualitative research will help to inform
the optimal design of a full-scale randomised trial.
Interim analyses
There are no planned interim between-group analyses.
However, progress with recruitment and retention is
monitored monthly by the TMG. If progress is below
target, strategies will be implemented to improve progress
in discussion with the TSC.
Trial management and oversight
The trial co-ordinating centre will be the Nottingham
Clinical Trials Unit (NCTU). Trial oversight will be by
an independent Trial Steering Committee (TSC), which
will meet at least twice a year and will provide an inde-
pendent assessment of whether a full trial is feasible. As
this is a feasibility study and both trial interventions are
widespread clinical practice, there will be no independent
Data Monitoring Committee.
The Trial Management Group (TMG) will meet
monthly, and be responsible for the day-to-day manage-
ment of the trial. Members of the TMG will report to
the TSC at their meetings.
Protocol amendments
The methods described in this protocol reflect the current
study protocol (v 2.0 dated 21 June 2016). This protocol
conforms to Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) recommendations
(see Additional file 1 and Fig. 2). A summary of
protocol amendments can be seen in Table 1. Allrotocol
r to start of recruitment
typographical changes
icipant requires treatment on more than one finger, then both/all fingers
e manner (i.e. both/all with limited fasciectomy or both/all with needle
y outcomes that require reference to a single finger, the one which the
tively as causing the most trouble will be selected
r start of recruitment
follow-up so that participants who are unable to have a 6-month visit
p period, because of the waiting time from randomisation to surgery,
ostal questionnaire only
litative research is carried out by researchers from the University of
nts may pause or stop audio-recordings or discussions with the
any time
verse event (SAE) reporting timelines and process
Harrison et al. Trials  (2017) 18:392 Page 10 of 12amendments to the protocol and associated paperwork
have been approved by the trial sponsor, Research
Ethics Committee and local R&D departments prior to
implementation.
Confidentiality
Information about participants will be stored anonym-
ously, confidentially and securely, and will be managed
according to the requirements of the Data Protection
Act, the NHS Caldicott Guardian and Research Govern-
ance Framework for Health and Social Care, conditions
of REC approval and NHS information governance
policy. Participant confidentiality will be ensured using
unique identification numbers. Patient-identifiable infor-
mation will be stored in locked filing cabinets in a secure
room. Study data may be shared with the University of
Bristol and other organisations as relevant where
consent to do so has been obtained.
Post-trial care
On completion of the study, participants will continue
to receive routine NHS care as appropriate.
Dissemination
The trial results will be reported in a peer-reviewed jour-
nal, and presented at scientific meetings. Reporting will be
in compliance with CONSORT recommendations. Results
will be made available to participants through a newsletter
if they provide consent to receive this.
Discussion
The current lack of robust evidence on treatment for
Dupuytren’s contractures of the fingers means that the
choice of treatment mainly depends on surgeon and
patient preferences. A comparison of NF with LF has
been identified as an important research question for
both surgeons and patients [5]. However, it is uncertain
whether surgeons will be willing to recruit, and whether
patients will be willing to be randomised to such a study
of two treatments which have very different patient path-
ways. Social circumstances, such as self-employment,
duties as a carer for a relative and the financial burden of
prolonged sick leave, may all influence each patient’s treat-
ment preference, as may the desire for a straight, aesthet-
ically satisfying finger, or to minimise the risk of needing
further surgery in the future. Although some surgeons are
confident with NF and willing to treat patients with well-
defined cords causing either MCP or PIP joint contrac-
tures, others are reluctant to treat PIP contractures as they
are concerned about damaging a digital nerve and also
may not consider NF successful in treating these particu-
lar contractures. This is despite a large series reporting
low incidences of digital nerve damage with NF [33] and a
general acceptance that all procedures are less good atstraightening PIP contractures than MCP ones. From a
patient’s perspective, the options of NF and LF offer very
different short- and long-term benefits, and thus many
may find one treatment option suits their lifestyle much
better than the other. The integrated qualitative and QRI
component of the HAND-1 study will provide fundamen-
tal insights into the feasibility and design of a main trial.
The assessment of outcome of Dupuytren’s treatment
with PROMs is in its infancy, and success or failure of
the treatment has previously been determined by the
amount of angular correction (straightening) of the
flexed finger and the subsequent amount of recurrent
angular deformity occurring over a pre-set time period,
regardless of whether this results in the patient wishing
to undergo further treatment to straighten the finger
again. This is particularly unsatisfactory as the relation-
ship between hand and finger function and joint-angle
deformity is controversial.
The HAND-1 feasibility study will provide data essential
to design and conduct a successful, future multicentre trial
comparing the outcomes and costs of NF with LF for the
treatment of Dupuytren’s contracture. This will provide
robust evidence to guide clinical decision-making.
Trial status
The HAND-1 study is ongoing. Recruitment commenced
in November 2015 and is expected to continue until 30
September 2016.
Additional file
Additional file 1: SPIRIT Checklist. (DOC 120 kb)
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